Malcisbo - the sweet vaccines company

Malcisbo develops novel carbohydrate-based vaccines for human & animal health. Based on a novel platform technology, we develop vaccines against bacterial  diseases.

Our development projects are:

Campylobacter explained by EFSA (European Food Safety Authority)

As antibiotic resistance has reached alarming levels all over the world, alternative solutions are needed. Vaccines have been proven to be one of the most effective pillars of prevention.

EFSA on antimicrobial resistance in the EU and on increasing problems to treat foodborne bacteria, like Campylobacter.

 

Latest News

  • 11 January 2020

    Malcisbo has been selected as emerging company to present at the Animal Health Investment Forum in London (Feb 2020)

  • 21 January 2019

    Malcisbo has been selected as emerging company to present at the Animal Health Investment Forum in London (Feb 2019)

  • 26 November 2018

    VetBioNet grant

    Malcisbo wins a grant to perform an APP challenge trial in a BLS3 facility.